Track topics on Twitter Track topics that are important to you
LAS VEGAS, July 23, 2015 (GLOBE NEWSWIRE) -- GrowBLOX Sciences, Inc. (OTCQB:GBLX), a biopharmaceutical company with state-of-the-art technologies in plant biology and cultivation designed to produce consistent medicinal cannabis, today announced that over the course of the next few weeks certain changes in management personnel and operating procedures would soon be implemented in preparation for the commencement of cultivation operations through our majority-owned subsidiary, GB Sciences Nevada, LLC.
CEO Craig Ellins shared that “The build out of our principal cultivation facility in Nevada is proceeding well and on schedule. As we transition from our engineering intensive development stage, involving largely R&D and licensure efforts, to the day-to-day operations of producing an excellent product, branding it appropriately, and maximizing our revenue, we will need to significantly beef up our staff. We have brought in John Poss as a consultant to put in effect some of these changes. We feel that John will be instrumental in helping us to achieve that transition smoothly and expeditiously.”
John Poss, a former CPA, is a Senior Executive with success in improving performance in technology, logistics, operations, business systems and finance. His experience includes CEO, COO, CFO and CTO of both public and private companies with sales ranging from $10 million to $450 million as well as over 15 years of consulting experience. He also has extensive M&A experience, both buy and sell side, including private equity. He also holds two United States patents.
Some of the anticipated changes and additions to the operations team include appointing a General Manager for the GBS Nevada Venture in the near future as well as support staff for the 30,000sqft cultivation facility.
The key personnel for the retail location in Las Vegas as well as the delivery service will also be put in place in the upcoming weeks. Product development and scientific validation of consumer facing products will be managed by a combination of in-house scientists and contracted chemists and formulators.
Chief Science Officer, Dr. Andrea Small-Howard, shared that “Our drug discovery strategy and clinical research will be enhanced by the success of our Nevada operations. Profiling proprietary strains for their therapeutic properties is essential for the scientific and medical evolution of cannabis. Our competitive advantage lies in the privilege to legally grow and scientifically study medical cannabis here in Nevada. It is extremely important to our shareholders that we have the ability to test and develop products on a commercial scale but with laboratory precision.”
In connection with those planned changes, the company has replaced its PCAOB auditor with Patrick Heyn, CPA, who was the concurring auditor for the company’s most recent audited statement, and expects to shortly announce further additions of key personnel to manage the revenue-producing operations expected to begin in the early fourth quarter of 2015.
About GrowBLOX Sciences, Inc.
GrowBLOX Sciences, Inc. (OTCQB:GBLX) is a biopharmaceutical research and development company focused on creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. The Company has leading technology and cannabis industry processes, with a “big” data-driven clinical research and development loop to bring relief to patients in communities across the country. Through our GBS PR subsidiary, we are developing and globally distributing our GrowBLOXTM suite of cultivation and growing chambers. To learn more about GrowBLOX Sciences, Inc., go to www.growblox.com.
Forward-Looking Statements: This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as presently constituted.
For more Information:
GrowBLOX Sciences, Inc., 6450 Cameron Street, Suite 110A, Las Vegas, NV 89118 866.721.0297 Craig Ellins, CEO; Andrea Small Howard, Chief Science Officer.
GrowBLOX is a registered trademark of GrowBLOX Sciences, Inc.NEXT ARTICLE
Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering whe...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...